Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous plus intracranial ipilimumab and nivolumab in recurrent glioblastoma
2023-508278-26-01Phase 2Authorised
- Sponsor
- UZ Brussel
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and nivolumab in glioblastoma (GBM), sponsored by UZ Brussel. Planned start Mar 2024; status: authorised.
02
Drugs
ipilimumabnivolumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2023-508278-26-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508278-26-01.